Er,Cr:YSGG and Diode Lasers in the Treatment of Peri-implantitis

NCT04730687 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2021-04-19

No results posted yet for this study

Summary

In this study, 940 nm diode laser and 2780 nm erbium, chromium doped: yttrium, scandium, gallium, garnet (Er, Cr: YSGG) laser were used in the non-surgical treatment of peri-implant diseases in addition to mechanical treatment. And the effects of dental lasers on clinical parameters and matrix metalloproteinase 9 (MMP-9) and tissue inhibitors of matrix metalloproteinases-1 (TIMP-1) levels in peri-implant crevicular fluid were evaluated.

Conditions

  • Peri-Implantitis

Interventions

DEVICE

Traditional non surgical mechanical therapy

Mechanical instrumentation in all groups was made with titanium Gracey curettes (8mm in diameter, Langer ½, item code: 7103, Kohler Medizintechnik, GmbH \& Co, Ltd, Stockach, Germany).

DEVICE

Diode laser assisted non-surgical mechancal therapy

One week after mechanical treatment, a 940 nm diode laser (Ezlase®, Biolase Technology, Inc., San Clemente, CA) with a 300 µm diameter optical fiber tip applied approximately 1 mm above the most apical part of the peri-implant pocket, parallel to the implant surface (E3-9 mm).

DEVICE

Er, Cr: YSGG laser-assisted non-surgical mechanical therapy

1 week after mechanical treatment, 2780 nm Er, Cr: YSGG laser (Waterlase®, Biolase Technology, Inc., San Clemente, CA), short pulse '' H '' with 500 µm diameter fiberoptic periodontal tip (RFPT5-14 mm) mode has been applied.

Sponsors & Collaborators

  • Yuzuncu Yıl University

    lead OTHER

Principal Investigators

  • Nazli Zeynep Alpaslan Yayli, PhD · Yuzuncu Yıl University

  • Ahmet Cemil Talmac, PhD · Yuzuncu Yıl University

  • Serap Keskin Tunc, PhD · Yuzuncu Yıl University

  • Damla Akbal, PhD · Yuzuncu Yıl University

  • Dicle Altindal, PhD · Yuzuncu Yıl University

  • Abdullah Seckin Ertugrul, Professor · Izmir Katip Celebi University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
35 Years
Max Age
62 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-01-15
Primary Completion
2020-08-15
Completion
2020-08-15

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04730687 on ClinicalTrials.gov